CD8A and neoplasm: To ascertain whether macrophage activation by TLR5 agonist treatment promotes the activation and tumor infiltration of CD8+ T and NK cells, tumor-infiltrating immune cells and splenocytes from tumor-bearing mice were analyzed using flow cytometry.